NextPlat NXPL
NASDAQ NXPL
$9.13 -0.30 (-3.18%)
At close: Sep 4, 2026 · 4:00 PM EDT

NextPlat (NXPL) Liabilities and Shareholders Equity (2010 - 2026)

NextPlat's (NXPL) quarterly Liabilities and Shareholders Equity came in at $28.7 million in Q2 2026, down 7.61% year-over-year from $31.0 million in Q2 2025, and up 6.52% quarter-over-quarter from $26.9 million in Q1 2026.

Analysis

NextPlat (NXPL) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends

NextPlat (NXPL) has reported Liabilities and Shareholders Equity for 16 consecutive years, with $28.7 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 7.61% year-over-year to $28.7 million in Q2 2026; TTM through Jun 2026 was $113.1 million, a 21.71% decrease from a year earlier, with the FY2025 full-year figure at $27.5 million, down 25.92% from the prior year.
  • Liabilities and Shareholders Equity was $28.7 million for Q2 2026 at NextPlat, up from $26.9 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $66.2 million in Q3 2023 and troughed at $20.5 million in Q3 2022.
  • A 5-year average of $36.8 million and a median of $30.5 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
  • Across the five-year window, Liabilities and Shareholders Equity surged 835.88% in 2022 and sank 45.89% in 2025, its largest moves.
  • Over 5 years, Liabilities and Shareholders Equity stood at $28.6 million in 2022, then jumped by 125.07% to $64.5 million in 2023, then slumped by 42.49% to $37.1 million in 2024, then declined by 25.92% to $27.5 million in 2025, then rose by 4.39% to $28.7 million in 2026.
  • The last three Liabilities and Shareholders Equity figures came in at $28.7 million (Q2 2026), $26.9 million (Q1 2026), and $27.5 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Teva Pharmaceutical Industries 42.34 Bn 38.68 Bn 2.15 Bn 39.86 Bn
2 Viatris 19.39 Bn 18.50 Bn 1.46 Bn 35.04 Bn
3 Dr Reddys Laboratories 9.99 Bn 9.85 Bn 396.53 Mn 6.08 Bn
4 Amneal Pharmaceuticals 5.57 Bn 5.53 Bn 334.51 Mn 3.78 Bn
5 Bausch Health Companies 2.45 Bn 1.58 Bn 2.10 Bn 24.79 Bn
6 Ani Pharmaceuticals 1.70 Bn 1.34 Bn 165.89 Mn 1.49 Bn
7 Alvotech 1.66 Bn 1.52 Bn 2.56 Mn 1.59 Bn
8 Amphastar Pharmaceuticals 985.90 Mn 695.77 Mn 93.47 Mn 1.74 Bn
9 Fennec Pharmaceuticals 434.07 Mn 392.82 Mn 17.15 Mn 75.75 Mn
10 NextPlat 24.77 Mn 12.93 Mn 4.69 Mn 28.67 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 28.67 Mn
Mar 31, 2026 26.92 Mn
Dec 31, 2025 27.47 Mn
Sep 30, 2025 30.01 Mn
Jun 30, 2025 31.03 Mn
Mar 31, 2025 35.20 Mn
Dec 31, 2024 37.08 Mn
Sep 30, 2024 41.10 Mn
Jun 30, 2024 51.46 Mn
Mar 31, 2024 65.06 Mn
Dec 31, 2023 64.47 Mn
Sep 30, 2023 66.20 Mn
Jun 30, 2023 30.91 Mn
Mar 31, 2023 27.71 Mn
Dec 31, 2022 28.64 Mn
Sep 30, 2022 20.54 Mn
Jun 30, 2022 25.09 Mn
Mar 31, 2022 25.63 Mn
Dec 31, 2021 20.57 Mn
Sep 30, 2021 20.16 Mn